REDWOOD CITY, Calif., July 06, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today ...

D Molecular Therapeutics remains a Buy as 4D-150 enters phase 3 for wet AMD/DME, cutting injections up to 87%. Click for more ...

Missed injections for weeks or months can trigger vision damage that isn't always fully reversible in patients with neovascular age-related macular degeneration (wet AMD), according to Carl Regillo, ...

ALPHARETTA, Ga., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the ...

REDWOOD CITY, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly ...

-- More than half of patients free of injection at median follow-up of 1.7 years at 2 x 10^11 vg/eye -- “We have now followed all wet AMD patients in the OPTIC trial for a minimum of a year, and in ...

Wet age-related macular degeneration (AMD) is an eye condition that threatens the middle of your eyesight. It’s caused when abnormal blood vessels in your eyes leak fluid, damaging the part of your ...

Please provide your email address to receive an email when new articles are posted on . FORT LAUDERDALE, Fla. — In this Healio Video Perspective, Michael A. Singer, MD, discusses promising results for ...

Please provide your email address to receive an email when new articles are posted on . Researchers linked higher frequency of intravitreal anti-VEGF injections with a greater risk for mild cognitive ...

Patients with neovascular age‑related macular degeneration (AMD) whose retinal fluid cleared within 12 weeks of starting faricimab were more likely to have longer intervals between injections later in ...